|
|
|
|
|
HONG KONG, July 21, 2020 - (ACN Newswire) - Genor Biopharma Co. Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing oncology and autoimmune therapeutics, announced that the new drug application (NDA) for Geptanolimab, a novel PD-1 mAb drug candidate, has been accepted by the National Medical Products Administration ("NMPA") for the treatment of Peripheral T cell Lymphoma (PTCL).
On the same day, Genor Biopharma announced the appointment of Mr. CHEN Wende as Chief Operation Officer. In this role, Mr. CHEN will oversee commercialization and prepare for launches of late-stage drug candidates.
Mr. CHEN brings over 20 years of experience in biopharmaceutical industry, focusing on sales and marketing and business operation at Roche, AstraZeneca, and Pfizer in China. Mr. CHEN was most recently Chief Commercial Officer at a well-known biotech company. Before that, Mr. CHEN served as Vice President at Roche China, overseeing Corporate Affairs, Market Access and Channel Management for a number of key drugs including Herceptin, MabThera, Avastin, Tarceva and Zelboraf. Mr. CHEN also served as Senior Vice President at AstraZeneca from 2010 and as Senior Sales Director at Pfizer from 2000.
"We are excited to appoint Mr. CHEN as COO of Genor Biopharma. We are looking to file NDAs for a number of our late-stage drug candidates in the near term," commented Dr. GUO, Chief Executive Officer of Genor Biopharma, "With over 20 years of experience in drug commercialization and deep insight of the landscape, Mr. CHEN will build our in-house commercialization team and lead our drug launches with differentiated strategy and drive our transformation into a biopharma company."
About JHBP (CY) Holdings Limited ("Genor Biopharma")
Established in December 2007, JHBP (CY) Holdings Limited is a biopharmaceutical powerhouse focusing on developing and commercializing oncology and autoimmune drugs. The Company has been strategically focused on major therapeutic areas with substantial unmet medical needs. At present, the Company has more than 10 drug candidates, 10 of which have entered the clinical development stage. The Company's pipeline products are mainly deployed in the field of cancer and other major diseases and have established a series of mature technology platforms in antibody drug research, development and manufacturing to serve patients in China and around the world. The Company's leadership team boasts more than 20 years of industry experience in global biopharmaceutical companies such as Pfizer, Merck, Amgen and AbbVie with proven track record and a well-balanced combination of expertise. The Company currently has around 400 employees across 3 sites in China - Shanghai Zhangjiang, Yunnan Yuxi, and Beijing office, as well as lab in South San Francisco, US, among which 80% are R&D and clinical specialists.
Topic: Press release summary
Source: Genor Biopharma
Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
GA-ASI Completes Qualification Testing for UK Protector Weapons
July 20, 2026 22:32 HKT/SGT
|
|
|
HKTDC showcases Hong Kong Tech Pavilion at WAIC 2026
July 20, 2026 21:19 HKT/SGT
|
|
|
Grand Opening of Lukfook Jewellery's New VivoCity Shop 
July 20, 2026 20:50 HKT/SGT
|
|
|
Graphene Manufacturing Group to Host Live Fireside Chat on Scaling Production and Expanding Global Markets
July 20, 2026 20:29 HKT/SGT
|
|
|
GA-ASI and KONGSBERG Advance JSM Integration for MQ-9B
July 20, 2026 18:05 HKT/SGT
|
|
|
INVEST Fair 2026 Kicks Off, Bringing Malaysia's Investing, Money and Finance Conversations to Life
July 20, 2026 09:31 HKT/SGT
|
|
|
Asia Pacific's Payments Industry Moves to Write Global Rulebook on AI Agent Liability
July 20, 2026 09:00 HKT/SGT
|
|
|
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
Friday, July 17, 2026 11:24:00 PM
|
|
|
Hitachi and NVIDIA collaborate to advance HMAX and enable end-to-end autonomous operations through the integrated control of physical AI
Friday, July 17, 2026 10:35:00 PM
|
|
|
Toyota's First "BE creation" Spin-Off Begins Operations in Japan
Friday, July 17, 2026 10:00:00 PM
|
|
|
|
|
More Press release >> |
|
 |
|
 |
|
